Dose-Response Relationship of Single Intravenous Remimazolam on Bispectral Index and Cardiorespiratory Effects Authors: Jianxiao Chen, Jianqiao Luo, Honglan Ye, Hao Lv, Wenyao Li, Fangfang Luo, Youmei Zhou, Fei Xiao, Chen Lv, Xiaowen Guo, Shaoqiang Huang Published: 2026 ABSTRACT BackgroundThe Bispectral Index (BIS) is a standardized, continuous measure of sedation depth. Studies have shown that remimazolam can induce a decrease in BIS, but the dose-response relationship between single-dose remimazolam and BIS remains unclear.PurposeThis study aimed to explore the correlation between single intravenous doses of remimazolam and BIS, and to observe its effects on respiration and circulation.Patients and MethodsThis was a prospective, randomized, double-blind, dose-finding study. One hundred patients scheduled for elective surgery under general anesthesia were randomly assigned to five groups and received intravenous remimazolam at 0.2, 0.3, 0.4, 0.5, or 0.6 mg/kg before anesthesia induction. BIS values at each time point, minimum BIS (BISmin), vital signs, adverse events, and interventions were recorded. Probit regression was used to calculate the ED50 and ED90 for the BIS ≤ 60 threshold (primary exploratory analysis), and a post hoc exploratory analysis was performed using the BIS ≤ 65 threshold.ResultsBIS values decreased more significantly with increasing remimazolam doses, with a plateau effect observed above 0.4 mg/kg. The BISmin values for each group were 60.6 ± 10.4, 58.4 ± 9.2, 58.1 ± 6.2, 55.6 ± 7.9, and 55.0 ± 6.4, respectively. Using the BIS ≤ 60 threshold, the ED50 and ED90 were 0.317 mg/kg (95% CI: 0.187–0.415 mg/kg) and 1.172 mg/kg (95% CI: 0.704–13.959 mg/kg), respectively. The extremely wide confidence interval for the ED90 reflects the statistical fact that the Probit model could not reliably extrapolate the dose-response relationship at higher doses within the studied range. Using the BIS ≤ 65 threshold in a post hoc exploratory analysis, the ED50 and ED90 were 0.147 mg/kg (95% CI: 0.024–0.216 mg/kg) and 0.436 mg/kg (95% CI: 0.334–0.958 mg/kg), respectively, with relatively narrower confidence intervals. Sensitivity analysis after excluding one patient who received ciprofol rescue was consistent with the primary analysis. There were no significant differences between groups in the incidence of tachycardia, bradycardia, hypoxemia, apnea, injection pain, body movement, diaphragmatic spasm, or cough, nor in the need for interventions. No serious adverse events occurred.ConclusionA dose-dependent relationship exists between single-dose remimazolam and BIS, with good respiratory and circulatory safety in the 0.2–0.6 mg/kg range and a plateau effect above 0.4 mg/kg. The extremely wide confidence interval for the ED90 estimated using the BIS ≤ 60 threshold suggests that this endpoint may not be suitable for pharmacodynamic evaluation of single-dose remimazolam. The ED estimates obtained with the BIS ≤ 65 threshold are from a post hoc exploratory analysis and await prospective validation in future studies incorporating clinical sedation assessments, such as the Modified Observer’s Assessment of Alertness/Sedation (MOAA/S) scale. Introduction Bispectral Index (BIS) monitoring can prevent residual consciousness caused by persistent or intermittent suboptimal effective anesthetic drug concentrations in the cerebral cortex, avoid potential adverse reactions associated with drug overdose, and provide an intuitive basis for clinical assessment.1 Propofol has a strong correlation with BIS,2 but it can easily cause respiratory and circulatory depression, and prolonged or high-dose infusion may lead to hyperkalemia, heart failure, or even cardiac arrest.3 The classic benzodiazepine sedative midazolam has individualized sedative effects, and its active metabolites retain sedative function,4 even at supra-sedative doses, it can not induce BIS below 60,5 suggesting that BIS may not be ideal for assessing its sedation level.1 Remimazolam, a water-soluble derivative of midazolam, has rapid onset and strong controllability6,7 and is used for procedural sedation and general anesthesia induction and maintenance.8 Systematic studies on the dose-response relationship between single-dose remimazolam and BIS are still limited. The primary objective of this study was to explore the dose-response relationship between different single doses of remimazolam and BIS, and to observe its effects on respiration and circulation, with ED50 and ED90 estimation using the traditional general anesthesia sedation threshold as a supportive analysis. Considering that previous literature suggests the traditional BIS ≤ 60 threshold may have limitations when applied to remimazolam,2,6,9–12 this study also planned a post hoc exploratory analysis using the BIS ≤ 65 threshold to provide preliminary reference information. Materials and Methods Study Design and Participants This was a prospective, single-center, randomized, double-blind, dose-finding study approved by the Ethics Committee of Shangyu Maternal and Child Health Hospital, Shaoxing, Zhejiang (Ethics No.: LL-2024-07-26; Ethics Committee Chair: Li Wang), and registered with the Chinese Clinical Trial Registry (https://www.chictr.org.cn; Registration No.: ChiCTR2400088425; Principal Investigator: Jianxiao Chen; Registration Date: August 19, 2024). Written informed consent was obtained from all patients before enrollment. The trial was conducted at Shangyu Maternal and Child Health Hospital, Shaoxing, Zhejiang, in accordance with the Declaration of Helsinki and CONSORT guidelines. Inclusion criteria: age 18–65 years, ASA physical status I–II, body mass index (BMI) 18–28 kg/m2, scheduled for elective surgery under general anesthesia. Exclusion criteria: obstructive sleep apnea syndrome, bronchiectasis, asthma, uncontrolled hypertension (systolic blood pressure >160 mmHg or diastolic blood pressure >100 mmHg), cardiac insufficiency (NYHA class III–IV),13 pulmonary insufficiency (moderate-to-severe COPD), hepatic insufficiency (Child-Pugh class B/C),14 renal insufficiency (eGFR <60 mL/min/1.73m2), history of severe central nervous system disease, diabetes (HbA1c ≥9%), neuromuscular disease, intolerance or allergy to benzodiazepines, allergy or suspected allergy to study drugs, history of antipsychotic or antidepressant use, alcohol or drug dependence, pre-induction BIS <80, potential difficult airway (Mallampati >2), patient refusal, or other conditions deemed unsuitable by the anesthesiologist. Randomization and Blinding A statistician not involved in observation or research used SPSS 27.0 (IBM) software to generate a 1:1:1:1:1 randomization sequence, assigning participants to five groups: remimazolam 0.2 mg/kg (R0.2 group), 0.3 mg/kg (R0.3 group), 0.4 mg/kg (R0.4 group), 0.5 mg/kg (R0.5 group), and 0.6 mg/kg (R0.6 group). Each allocation result was placed in an opaque sealed envelope. An anesthesia nurse not involved in observation or assessment opened the envelopes sequentially before anesthesia and prepared the study drugs accordingly. All groups received remimazolam diluted to 20 mL with 0.9% saline (20 mL syringe). The anesthesiologist administering the drug and the another anesthesiologist responsible for observation and recording were both blinded to group allocation. Anesthesia Management and Intervention All patients fasted for 8 hours before surgery and received no premedication. Upon arrival in the operating room, standard monitoring was applied, including non-invasive blood pressure, electrocardiography, Saturation of peripheral oxygen (SpO2), and BIS, with end-tidal CO2 waveform for respiratory monitoring. Patients received 6 mL/kg sodium-potassium-calcium-magnesium glucose injection via peripheral intravenous infusion over 30 minutes, and inhaled 100% oxygen via mask for at least 3 minutes before remimazolam administration. Baseline SBP, DBP, HR, SpO2, and BIS (after 1 minute of stabilization) were recorded. Baseline SBP, DBP, and HR were taken as the mean of three consecutive measurements (1-minute intervals). The study dose of remimazolam (National Drug Approval No. H20190034, Hengrui Pharmaceutical Co., Ltd.) was administered via an intravenous infusion pump at a constant rate over 30 seconds. The non-invasive blood pressure measurement was initiated immediately after drug administration, and BIS monitoring continued for 5 minutes after drug administration. If BIS ≥80 during the observation period, intravenous ciprofol 0.2 mg/kg was administered as rescue, and subsequent BIS values were taken as the last value before ciprofol administration. At the end of the observation period (T300), if BIS ≤65, patients received intravenous sufentanil 0.4 μg/kg and rocuronium 1.0 mg/kg, followed by tracheal intubation under video laryngoscopy after adequate muscle relaxation. If BIS >65 at T300, intravenous ciprofol 0.2 mg/kg was administered (repeated if necessary), followed by sufentanil and rocuronium once BIS ≤65 was achieved, and tracheal intubation was performed. Hypotension was defined as a decrease in systolic blood pressure exceeding 30% of baseline (excluding interference from relatively low baseline blood pressure);15,16 hypertension was defined as an increase in systolic blood pressure exceeding 30% of baseline;15,17 tachycardia was defined as heart rate >100 bpm; bradycardia was defined as heart rate <60 bpm. Apnea was defined as complete loss or marked reduction (≥90% decrease) of CO2 waveform lasting ≥10 seconds,18 managed by jaw-thrust maneuver. Hypoxemia was defined as SpO2≤90% during oxygen supplementation, managed by mask-assisted ventilation, with intubation if necessary. Injection pain was defined as patient-reported pain or withdrawal response of the infusion arm. Body movement was defined as movement of any body part other than the infusion arm during drug injection. Hypotension was treated with norepinephrine 4 μg per dose; hypertension with urapidil 10 mg per dose; heart rate >120 bpm with esmolol 0.5 mg/kg; heart rate <45 bpm with atropine 0.5 mg per dose. These measures could be repeated as necessary, with emergency preparedness maintained. Outcome Measures Primary outcome measure: BIS values. Recording time points: before drug administration, and at 0, 30, 60, 90, 120, 150, 180, 210, 240, 270, and 300 seconds after drug administration, designated as Pre-induced, T0, T30, T60, T90, T120, T150, T180, T210, T240, T270, and T300. Secondary outcome measures: Hemodynamic parameters (SBP, DBP, HR, SpO2), recorded at pre-drug, and 0, 60, 120, 180, 240, and 300 seconds after drug administration (Pre-induced, T0, T60, T120, T180, T240, T300). Incidence of hypoxemia, apnea, injection pain, body movement and diaphragmatic spasm. Exploratory outcome measures: BISmin (the minimum BIS value within 300 seconds) and based on this, the duration of effective sedation (time with BIS ≤60 and BIS ≤65, in seconds). Statistical Analysis Sample size was estimated based on pre-experimental results. In the pre-experiment, the sedation success rates (using BIS ≤60 as the effective sedation criterion) for the lowest dose group (0.2 mg/kg) and highest dose group (0.6 mg/kg) were 45.45% and 93.33%, respectively. With α = 0.05 (two-sided), β = 0.1, and equal group sizes, PASS 11.0 (NCCS) calculated a sample size of 16 per group. Considering potential dropout rates, 20 patients per group were ultimately set, with a total sample size of 100. The Shapiro–Wilk test and Levene’s test were used to assess normality and homogeneity of variance for continuous variables. Normally distributed data were expressed as mean ± standard deviation (SD) and compared between groups using one-way analysis of variance (ANOVA), with post-hoc pairwise comparisons using Tukey’s HSD test. Non-normally distributed data were expressed as median (Q1, Q3) and compared using the Kruskal–Wallis H-test, with post-hoc pairwise comparisons using Dunn’s test. Repeated-measures ANOVA was used to compare BIS values and vital signs (SBP, DBP, HR, SpO2) across time points, with Tukey’s HSD test for multiple comparisons. All tests were two-tailed, and adjusted P values were reported when Tukey corrections were applied. Count data were expressed as number of cases (%), and comparisons were made using the chi-square test or Fisher’s exact test. All statistical analyses were performed using SPSS (version 27.0), and graphs were generated using GraphPad Prism (version 10.0). A P value <0.05 was considered statistically significant. Considering previous literature6,19,20 and our pre-experimental results, the effective sedation rates using both BIS ≤60 and BIS ≤65 criteria were calculated for each group, and Probit regression was used to estimate ED50 and ED90. The BIS ≤60 analysis was designated as the primary exploratory analysis, while the BIS ≤65 analysis was designated as a post hoc exploratory analysis. Results All 100 patients assessed for eligibility met the inclusion criteria, were randomly allocated to five groups, and were included in the final intention-to-treat analysis (Figure 1). Figure 1Consort recruitment diagram.The consort recruitment diagram outlines the process for a study involving 100 patients. All patients were assessed for eligibility and none were excluded. They were randomized into five groups, each receiving different doses of RMZ: 0.2 mg/kg, 0.3 mg/kg, 0.4 mg/kg, 0.5 mg/kg and 0.6 mg/kg, with 20 patients per group. Each group received the allocated intervention and no patients failed to receive it. During follow-up, all patients were observed for 300 seconds and no patients missed the observation. The analysis included all 20 patients from each group, totaling 100 patients analyzed.A consort recruitment diagram for a study with 100 patients allocated to five groups.Abbreviation: RMZ, remimazolam. Consort recruitment diagram. There were no statistically significant differences in baseline characteristics among the five groups, including age, sex, ASA classification, BMI, surgery type, comorbidities, and surgical history (all P >0.05) (Table 1).Table 1Baseline Patient CharacteristicsVariableGroup R0.2 (n=20)Group R0.3 (n=20)Group R0.4 (n=20)Group R0.5 (n=20)Group R0.6 (n=20)F/χ2P-valueAge (yr)43.4±12.243.5±9.144.1±10.943.5±11.843.4±11.60.0151.000Male/Female (n)4/164/165/153/174/160.1490.960ASA, I/II (n)9/116/149/1110/108/120.4400.769BMI (kg m−2)22.5±2.322.9±1.922.7±1.823.1±3.022.5±2.20.2850.928Surgery type(n)Gynecology6671081.5150.824Orthopaedics874424.8000.308Breast211132.0000.736Urology (male)103222.7500.600ENT222103.1430.534General143253.3330.504Comorbidity n (%)Diabetes1 (5)1(5)1(5)2(10)1(5)0.7090.724Hypertension0(0)0(0)0(0)0(0)2(10)8.1630.086Mild anemia1(5)0(0)0(0)1(5)0(0)3.0610.548Rheumatoid arthritis0(0)1(5)0(0)0(0)0(0)4.0400.401Hemophilia A0(0)0(0)1(5)0(0)0(0)4.0400.401Sicca syndrome0(0)0(0)0(0)1(5)0(0)4.0400.401Urticaria1(5)0(0)0(0)0(0)0(0)4.0400.401Operation history n (%)10(50)11(55)4(20)7(35)10(50)6.8140.146Notes: The measurement data were expressed as values are mean ± SD, ANOVA was used for comparison between groups. Count data (gender, ASA classification, surgery type, comorbidity and operation history) were expressed as number of patients, n (%), Fisher’s exact test was used for comparison between groups. There were no significant differences in the baseline characteristics.Abbreviations: R0.2, R0.3, R0.4, R0.5, R0.6 = Remimazolam at 0.2, 0.3, 0.4, 0.5, 0.6 mg·kg−1, respectively; ASA: American Society of Anesthesiologists; BMI, Body mass index. Table 1Baseline Patient CharacteristicsVariableGroup R0.2 (n=20)Group R0.3 (n=20)Group R0.4 (n=20)Group R0.5 (n=20)Group R0.6 (n=20)F/χ2P-valueAge (yr)43.4±12.243.5±9.144.1±10.943.5±11.843.4±11.60.0151.000Male/Female (n)4/164/165/153/174/160.1490.960ASA, I/II (n)9/116/149/1110/108/120.4400.769BMI (kg m−2)22.5±2.322.9±1.922.7±1.823.1±3.022.5±2.20.2850.928Surgery type(n)Gynecology6671081.5150.824Orthopaedics874424.8000.308Breast211132.0000.736Urology (male)103222.7500.600ENT222103.1430.534General143253.3330.504Comorbidity n (%)Diabetes1 (5)1(5)1(5)2(10)1(5)0.7090.724Hypertension0(0)0(0)0(0)0(0)2(10)8.1630.086Mild anemia1(5)0(0)0(0)1(5)0(0)3.0610.548Rheumatoid arthritis0(0)1(5)0(0)0(0)0(0)4.0400.401Hemophilia A0(0)0(0)1(5)0(0)0(0)4.0400.401Sicca syndrome0(0)0(0)0(0)1(5)0(0)4.0400.401Urticaria1(5)0(0)0(0)0(0)0(0)4.0400.401Operation history n (%)10(50)11(55)4(20)7(35)10(50)6.8140.146Notes: The measurement data were expressed as values are mean ± SD, ANOVA was used for comparison between groups. Count data (gender, ASA classification, surgery type, comorbidity and operation history) were expressed as number of patients, n (%), Fisher’s exact test was used for comparison between groups. There were no significant differences in the baseline characteristics.Abbreviations: R0.2, R0.3, R0.4, R0.5, R0.6 = Remimazolam at 0.2, 0.3, 0.4, 0.5, 0.6 mg·kg−1, respectively; ASA: American Society of Anesthesiologists; BMI, Body mass index. Baseline Patient Characteristics Notes: The measurement data were expressed as values are mean ± SD, ANOVA was used for comparison between groups. Count data (gender, ASA classification, surgery type, comorbidity and operation history) were expressed as number of patients, n (%), Fisher’s exact test was used for comparison between groups. There were no significant differences in the baseline characteristics. Abbreviations: R0.2, R0.3, R0.4, R0.5, R0.6 = Remimazolam at 0.2, 0.3, 0.4, 0.5, 0.6 mg·kg−1, respectively; ASA: American Society of Anesthesiologists; BMI, Body mass index. BIS showed significant dynamic changes over time (time main effect: F(11,1140) = 178.0, P <0.0001) and demonstrated a clear dose-dependent pattern (dose main effect: F(4,1140) = 25.35, P <0.0001). The difference between the low-dose group (0.2 mg/kg) and the medium-to-high dose groups (≥0.4 mg/kg) constituted the main source of the dose main effect. No significant differences in BIS were detected among the medium-to-high dose groups (R0.4, R0.5, R0.6) at any time point (all adjusted P >0.05), suggesting that the sedative effect reached a plateau above 0.4 mg/kg (Figure 2). Figure 2Comparison of the mean values of BIS in each group within 300s. Time course of Bispectral Index (BIS) values following administration of five doses of remimazolam (0.2, 0.3, 0.4, 0.5, and 0.6 mg/kg) from T30 to T300.Data are expressed as mean ± SD. Two-way repeated measures ANOVA revealed no significant interaction between dose and time (F(44,1140)=0.8886, P>0.05), with significant main effects for both time (F(11,1140)=178.0, P<0.0001) and dose (F(4,1140)=25.35, P<0.0001). Post-hoc multiple comparisons were performed using Tukey’s HSD test. *Adjusted P<0.05, **Adjusted P<0.01, ***Adjusted P <0.001 vs the 0.2 mg/kg group. Significant differences were predominantly observed between the 0.2 mg/kg group and higher-dose groups (≥0.4 mg/kg).A line graph with error bars shows BIS over time for five dose groups: 0.2 mg/kg, 0.3 mg/kg, 0.4 mg/kg, 0.5 mg/kg and 0.6 mg/kg. Time is marked at Pre-induced, 0s, 30s, 60s, 90s, 120s, 150s, 180s, 210s, 240s, 270s and 300s. BIS ranges from 50 to 100. 0.2 mg/kg: BIS starts at 95, drops to 87 at 0s and fluctuates between 65 and 72 thereafter. 0.3 mg/kg: Begins at 96, falls to 88 at 0s and ranges from 63 to 69. 0.4 mg/kg: Starts at 95, peaks at 90 at 0s, then varies from 62 to 67. 0.5 mg/kg: Begins at 96, dips to 83 at 0s and fluctuates between 59 and 64. 0.6 mg/kg: Starts at 95, drops to 85 at 0s and ranges from 60 to 65. Annotations indicate significant comparisons at 90s, 120s, 150s, 180s, 210s, 240s, 270s and 300s with asterisks.A line graph showing Bispectral Index over time for five remimazolam dose groups. Comparison of the mean values of BIS in each group within 300s. Time course of Bispectral Index (BIS) values following administration of five doses of remimazolam (0.2, 0.3, 0.4, 0.5, and 0.6 mg/kg) from T30 to T300.Data are expressed as mean ± SD. Two-way repeated measures ANOVA revealed no significant interaction between dose and time (F(44,1140)=0.8886, P>0.05), with significant main effects for both time (F(11,1140)=178.0, P<0.0001) and dose (F(4,1140)=25.35, P<0.0001). Post-hoc multiple comparisons were performed using Tukey’s HSD test. *Adjusted P<0.05, **Adjusted P<0.01, ***Adjusted P <0.001 vs the 0.2 mg/kg group. Significant differences were predominantly observed between the 0.2 mg/kg group and higher-dose groups (≥0.4 mg/kg). There were no statistically significant differences between groups in BISmin, number of cases with BISmin <50, BIS300 ≥80, BIS300 ≤65, or duration of BIS ≤60 (all P >0.05). The duration of BIS ≤65 was longer in the R0.6 group than in the R0.2 group (adjusted P = 0.008), with no other significant differences between groups (all adjusted P >0.05), suggesting that doses above 0.6 mg/kg significantly prolonged the duration of BIS ≤65 (Table 2).Table 2BIS-Related ParametersVariableGroup R0.2 (n=20)Group R0.3 (n=20)Group R0.4 (n=20)Group R0.5 (n=20)Group R0.6 (n=20)Test Statistic(F/χ2/H)P-valueBISmin (mean±SD)60.6±10.458.4±9.258.1±6.255.5±8.055.0±6.41.4130.187BISmin<50 n (%)2 (10%)3 (15%)2 (10%)6 (30%)5 (25%)4.4720.346BIS300≥80 n (%)3 (15)1 (10)0 (0)1 (5)1 (5)4.2550.373BIS300≤65 n (%)5 (25)7 (35)8 (40)12 (60)8 (40)5.4170.247Time for BIS≤60 (S)44.9±77.049.6±72.351.8±80.386.9±86.488.8±98.91.3320.264Time for BIS≤65 (S)15.0 (0.0,120.0)67.5 (26.3,165.0)135.0 (22.5,240.0)210.0 (60.0,277.5)232.5 (67.5,270.0) **13.9160.008Notes: Data are presented as mean ± SD, median (Q1, Q3), or n (%), as appropriate. BISmin and time for BIS≤60 were compared using one-way ANOVA, with test statistics (F values) shown. The rates of BISmin<50, BIS300≥80, and BIS300≤65 were compared using the chi-square test, with χ2 values reported. Time for BIS≤65 is presented as median (Q1, Q3) and was compared across the groups using the Kruskal–Wallis H-test (H = 13.916, P = 0.008), post-hoc pairwise comparisons were performed using Dunn’s test with Bonferroni correction, **P < 0.001 vs R0.2 group.Abbreviations: BISmin, the minimum of BIS within 300s; BIS300, the BIS value at 300 second; Time for BIS≤60, the duration of BIS ≤ 60 within 300s; Time for BIS≤65, the duration of BIS ≤65 within 300s. Table 2BIS-Related ParametersVariableGroup R0.2 (n=20)Group R0.3 (n=20)Group R0.4 (n=20)Group R0.5 (n=20)Group R0.6 (n=20)Test Statistic(F/χ2/H)P-valueBISmin (mean±SD)60.6±10.458.4±9.258.1±6.255.5±8.055.0±6.41.4130.187BISmin<50 n (%)2 (10%)3 (15%)2 (10%)6 (30%)5 (25%)4.4720.346BIS300≥80 n (%)3 (15)1 (10)0 (0)1 (5)1 (5)4.2550.373BIS300≤65 n (%)5 (25)7 (35)8 (40)12 (60)8 (40)5.4170.247Time for BIS≤60 (S)44.9±77.049.6±72.351.8±80.386.9±86.488.8±98.91.3320.264Time for BIS≤65 (S)15.0 (0.0,120.0)67.5 (26.3,165.0)135.0 (22.5,240.0)210.0 (60.0,277.5)232.5 (67.5,270.0) **13.9160.008Notes: Data are presented as mean ± SD, median (Q1, Q3), or n (%), as appropriate. BISmin and time for BIS≤60 were compared using one-way ANOVA, with test statistics (F values) shown. The rates of BISmin<50, BIS300≥80, and BIS300≤65 were compared using the chi-square test, with χ2 values reported. Time for BIS≤65 is presented as median (Q1, Q3) and was compared across the groups using the Kruskal–Wallis H-test (H = 13.916, P = 0.008), post-hoc pairwise comparisons were performed using Dunn’s test with Bonferroni correction, **P < 0.001 vs R0.2 group.Abbreviations: BISmin, the minimum of BIS within 300s; BIS300, the BIS value at 300 second; Time for BIS≤60, the duration of BIS ≤ 60 within 300s; Time for BIS≤65, the duration of BIS ≤65 within 300s. BIS-Related Parameters Notes: Data are presented as mean ± SD, median (Q1, Q3), or n (%), as appropriate. BISmin and time for BIS≤60 were compared using one-way ANOVA, with test statistics (F values) shown. The rates of BISmin<50, BIS300≥80, and BIS300≤65 were compared using the chi-square test, with χ2 values reported. Time for BIS≤65 is presented as median (Q1, Q3) and was compared across the groups using the Kruskal–Wallis H-test (H = 13.916, P = 0.008), post-hoc pairwise comparisons were performed using Dunn’s test with Bonferroni correction, **P < 0.001 vs R0.2 group. Abbreviations: BISmin, the minimum of BIS within 300s; BIS300, the BIS value at 300 second; Time for BIS≤60, the duration of BIS ≤ 60 within 300s; Time for BIS≤65, the duration of BIS ≤65 within 300s. The effective sedation rate using the BIS ≤60 criterion showed a dose-dependent trend (P = 0.05), with a significant difference between the R0.2 and R0.6 groups (P = 0.004). The effective sedation rate using the BIS ≤65 post hoc exploratory criterion also showed a dose-dependent trend (P = 0.041), with a significant difference between the R0.2 and R0.6 groups (P = 0.004) (Figure 3). Figure 3Comparison of effective sedation rates using BIS ≤ 60 versus BIS ≤ 65 as thresholds across five remimazolam dose groups (0.2–0.6 mg/kg). The BIS ≤ 65 threshold was defined as a post hoc exploratory criterion (this threshold was not pre-specified in the registered protocol). Under both criteria, effective sedation rates increased in a dose-dependent manner (BIS ≤ 60: P = 0.05; BIS ≤ 65: P = 0.041, by trend test), and pairwise comparisons showed significant differences between the R0.2 and R0.6 groups (both P = 0.004). *P < 0.05 vs R0.2 group.A line graph showing effective sedation rate by remimazolam dose for two BIS thresholds. Comparison of effective sedation rates using BIS ≤ 60 versus BIS ≤ 65 as thresholds across five remimazolam dose groups (0.2–0.6 mg/kg). The BIS ≤ 65 threshold was defined as a post hoc exploratory criterion (this threshold was not pre-specified in the registered protocol). Under both criteria, effective sedation rates increased in a dose-dependent manner (BIS ≤ 60: P = 0.05; BIS ≤ 65: P = 0.041, by trend test), and pairwise comparisons showed significant differences between the R0.2 and R0.6 groups (both P = 0.004). *P < 0.05 vs R0.2 group. Probit regression analysis estimated the ED50 and ED90 for BIS ≤60 as 0.317 mg/kg (95% CI: 0.187–0.415 mg/kg) and 1.172 mg/kg (95% CI: 0.704–13.959 mg/kg), respectively. The ED90 far exceeded commonly used clinical doses, with an extremely wide confidence interval reflecting the statistical fact that the Probit model could not reliably extrapolate the dose-response relationship within the studied dose range (Figure 4a). Figure 4(a) Dose-response curve of remimazolam for sedation rate with BIS ≤ 60 as efficacy criterion. The ED90 far exceeds the commonly used clinical dose, and with an extremely wide confidence interval indicating substantial uncertainty, its practical reference value is limited. (b) Dose–response curve of remimazolam for sedation rate using BIS ≤ 65 as the efficacy criterion (a post hoc exploratory threshold). In contrast to the BIS ≤ 60 analysis, the confidence interval is considerably narrowed. This finding is exploratory and requires prospective confirmation in a dedicated study.Image A: Line graph with square markers and a fitted curve. X-axis: remimazolam dose (mg/kg), 0.00 to 1.50. Y-axis: rate of BIS less than or equal to 60, 0.00 to 1.00. ED50: 0.317 mg/kg (95 percent CI: 0.187 to 0.415 mg/kg), ED90: 1.172 mg/kg (95 percent CI: 0.704 to 13.959 mg/kg). Points: (0.00, 0.00), (0.25, 0.50), (0.50, 0.70), (0.75, 0.80), (1.00, 0.85), (1.25, 0.90), (1.50, 0.95). Trend: increasing, plateaus near 0.95. Image B: Line graph with square markers and a fitted curve. X-axis: remimazolam dose (mg/kg), 0.0 to 0.6. Y-axis: rate of BIS less than or equal to 65 (exploratory), 0.00 to 1.00. ED50: 0.147 mg/kg (95 percent CI: 0.024-0.216 mg/kg), ED90: 0.436 mg/kg (95 percent CI: 0.334-0.958 mg/kg). Points: (0.0, 0.0), (0.1, 0.20), (0.2, 0.55), (0.3, 0.75), (0.4, 0.85), (0.5, 0.90), (0.6, 0.95). Trend: increasing, plateaus near 0.95. Comparison: BIS less than or equal to 65 curve reaches similar rates at lower doses than BIS less than or equal to 60 curve.Two line graphs showing remimazolam dose response for BIS min thresholds 60 and 65 sedation rates. (a) Dose-response curve of remimazolam for sedation rate with BIS ≤ 60 as efficacy criterion. The ED90 far exceeds the commonly used clinical dose, and with an extremely wide confidence interval indicating substantial uncertainty, its practical reference value is limited. (b) Dose–response curve of remimazolam for sedation rate using BIS ≤ 65 as the efficacy criterion (a post hoc exploratory threshold). In contrast to the BIS ≤ 60 analysis, the confidence interval is considerably narrowed. This finding is exploratory and requires prospective confirmation in a dedicated study. The post hoc exploratory analysis using the BIS ≤65 threshold yielded ED50 and ED90 values of 0.147 mg/kg (95% CI: 0.024–0.216 mg/kg) and 0.436 mg/kg (95% CI: 0.334–0.958 mg/kg), respectively, with relatively narrower confidence intervals (Figure 4b). One patient in the R0.2 group received ciprofol rescue at T280 due to BIS ≥80, with the T300 BIS value remaining 88. Sensitivity analysis excluding this patient showed BISmin values of 61.8 ± 6.2, 58.4 ± 9.2, 58.1 ± 6.2, 55.6 ± 7.9, and 55.0 ± 6.4 for each group (one-way ANOVA: F = 2.313, P = 0.063), and time for BIS ≤60 (seconds) of 41.7 ± 77.0, 49.6 ± 72.3, 51.8 ± 80.3, 86.9 ± 86.4, and 88.8 ± 98.9 (F = 7.253, P = 0.123). The recalculated ED50 and ED90 using the BIS ≤60 criterion were 0.339 mg/kg (95% CI: 0.224–0.426 mg/kg) and 0.998 mg/kg (95% CI: 0.668–4.041 mg/kg), consistent with the primary analysis. At T300, SpO2 in the R0.4 group was lower than that in the R0.2 group (adjusted P = 0.030), the R0.3 group (adjusted P = 0.0011), and the R0.5 group (adjusted P = 0.0064). However, this difference was not dose-dependent, and mean SpO2 values in all groups remained within the normal range (>95%). There were no significant differences in SBP, DBP, or HR between groups (all P >0.05) (Figure 5). Figure 5Comparison of SBP, DBP, HR and SpO2 in each group at each time. (a) Systolic blood pressure (SBP), (b) Diastolic blood pressure (DBP), (c) Heart rate (HR), and (d) Peripheral oxygen saturation (SpO2). Data are presented as mean ± SD. Two‑way repeated measures ANOVA revealed a significant dose‑by‑time interaction (F(24, 665)=1.540, P=0.0485). Post‑hoc simple effect analysis with Tukey’s HSD correction for multiple comparisons was performed at each time point. No significant differences were observed among groups at Pro‑induced, T0, T60, T120, T180, or T240 (all adjusted P>0.05). At T300, the R0.4 group showed significantly lower SpO2 compared with the R0.2 group (adjusted P=0.030), the R0.3 group (adjusted P=0.0011), and the R0.5 group (adjusted P=0.0064). All graphs were generated using GraphPad Prism (version 10.0).Image A: Graph of systolic blood pressure (SBP) over time (0 to 300 seconds). Y-axis: SBP in mmHg (90 to 150). Five dose groups (0.2 to 0.6 mg/kg) shown with different markers. SBP drops from 125 to 135 mmHg to 110-120 mmHg by 60 seconds, stabilizing at 108 to 118 mmHg. Image B: Diastolic blood pressure (DBP) graph, Y-axis: DBP in mmHg (50 to 90). DBP starts at 75 to 78 mmHg, decreases to 68 to 72 mmHg by 60 seconds, stabilizes at 65 to 70 mmHg. Image C: Heart rate (HR) graph, Y-axis: HR in bpm (60 to 100). HR increases from 70 to 74 bpm to 75 to 82 bpm at 0 seconds, remains at 74 to 83 bpm, then drops to 72 to 79 bpm. Image D: Peripheral oxygen saturation (SpO2) graph, Y-axis: SpO2 in percent (98.0 to 100.0). SpO2 stays around 99.0 to 100.0 percent, with the 0.4 mg/kg group slightly lower at 300 seconds. Lines overlap, indicating similar trends across doses. Blood pressure decreases post-induction, HR rises slightly and SpO2 remains stable near 99 to 100 percent with minimal dose impact.Multi-line graphs compare SBP, DBP, HR and SpO2 over time in five dose groups: 0.2, 0.3, 0.4, 0.5, 0.6 mg/kg. Comparison of SBP, DBP, HR and SpO2 in each group at each time. (a) Systolic blood pressure (SBP), (b) Diastolic blood pressure (DBP), (c) Heart rate (HR), and (d) Peripheral oxygen saturation (SpO2). Data are presented as mean ± SD. Two‑way repeated measures ANOVA revealed a significant dose‑by‑time interaction (F(24, 665)=1.540, P=0.0485). Post‑hoc simple effect analysis with Tukey’s HSD correction for multiple comparisons was performed at each time point. No significant differences were observed among groups at Pro‑induced, T0, T60, T120, T180, or T240 (all adjusted P>0.05). At T300, the R0.4 group showed significantly lower SpO2 compared with the R0.2 group (adjusted P=0.030), the R0.3 group (adjusted P=0.0011), and the R0.5 group (adjusted P=0.0064). All graphs were generated using GraphPad Prism (version 10.0). Three cases of systolic blood pressure below 90 mmHg (lowest 80 mmHg) occurred in the two high-dose groups. Although the decrease did not exceed 30% of baseline and thus did not meet the hypotension criterion, these patients received single-dose norepinephrine 4 μg intravenously and improved rapidly. No hypotension or hypoxemia occurred in any group. There were no significant differences between groups in the incidence of tachycardia, bradycardia, apnea, tongue base collapse, injection pain, body movement, diaphragmatic spasm, or cough, nor in the need for interventions (Table 3).Table 3Adverse Events and InterventionsVariableGroup R0.2 (n=20)Group R0.3 (n=20)Group R0.4 (n=20)Group R0.5 (n=20)Group R0.6 (n=20)χ2P-valueAdverse events (n, %)Tachycardia2 (10)0 (0)2 (0)2 (10)0 (0)4.2550.373Bradycardia1 (5)1 (5)0 (0)1 (5)2 (10)2.1050.716Apnea2 (10)5 (25)5 (25)4 (20)5 (25)2.0490.727Tongue base collapse (n, %)1(5)0(0)0(0)1(5)2(10)3.6460.456Injection pain2 (10)1 (5)2 (10)5 (25)6 (30)6.9940.136Body movement1 (5)2 (10)2 (10)5 (25)3 (15)4.0670.397Diaphragmatic spasm1 (5)1 (5)2 (10)2 (10)1 (5)0.9220.921Cough3 (15)1 (5)0 (0)0 (0)2 (10)6.0280.197Interventions (n, %)Jaw-thrust intervention2 (10)5 (25)5 (25)4 (20)5 (25)2.0490.727Norepinephrine4 μg IV0(0)0(0)0(0)2(10)1(5)4.2930.368Notes: number of patients, n (%); Fisher’s Exact Test was used for the analysis of adverse events and intervention measuring. Table 3Adverse Events and InterventionsVariableGroup R0.2 (n=20)Group R0.3 (n=20)Group R0.4 (n=20)Group R0.5 (n=20)Group R0.6 (n=20)χ2P-valueAdverse events (n, %)Tachycardia2 (10)0 (0)2 (0)2 (10)0 (0)4.2550.373Bradycardia1 (5)1 (5)0 (0)1 (5)2 (10)2.1050.716Apnea2 (10)5 (25)5 (25)4 (20)5 (25)2.0490.727Tongue base collapse (n, %)1(5)0(0)0(0)1(5)2(10)3.6460.456Injection pain2 (10)1 (5)2 (10)5 (25)6 (30)6.9940.136Body movement1 (5)2 (10)2 (10)5 (25)3 (15)4.0670.397Diaphragmatic spasm1 (5)1 (5)2 (10)2 (10)1 (5)0.9220.921Cough3 (15)1 (5)0 (0)0 (0)2 (10)6.0280.197Interventions (n, %)Jaw-thrust intervention2 (10)5 (25)5 (25)4 (20)5 (25)2.0490.727Norepinephrine4 μg IV0(0)0(0)0(0)2(10)1(5)4.2930.368Notes: number of patients, n (%); Fisher’s Exact Test was used for the analysis of adverse events and intervention measuring. Adverse Events and Interventions Notes: number of patients, n (%); Fisher’s Exact Test was used for the analysis of adverse events and intervention measuring. Discussion This study explored the correlation between single-dose remimazolam (0.2–0.6 mg/kg) and BIS, and observed its effects on respiration and circulation. The main findings included: a clear dose-dependent relationship between remimazolam dose and BIS, with a plateau effect above 0.4 mg/kg; good respiratory and circulatory safety within the 0.2–0.6 mg/kg range; the ED90 estimated using the BIS ≤60 criterion (1.172 mg/kg) far exceeded commonly used clinical doses21–24 with an extremely wide confidence interval (0.704–13.959 mg/kg), reflecting the statistical fact that the Probit model could not reliably extrapolate the dose-response relationship at higher doses within the studied range, suggesting a potential mismatch between this endpoint and single-dose remimazolam evaluation; the ED90 estimated using the BIS ≤65 post hoc exploratory criterion had a relatively narrower confidence interval (0.334–0.958 mg/kg), but since it was not combined with clinical sedation scales (eg, MOAA/S), it should be regarded as an exploratory finding based on this study. We observed significant non-linear decreases in BIS over time (P <0.0001), with BIS rapidly dropping to approximately 70 at T30. However, mean BIS values in all groups remained above 50, with the R0.2 group having the highest values,25,26 suggesting relatively light sedation. No significant differences in BIS were detected among the three medium-to-high dose groups (R0.4, R0.5, R0.6) at any time point, and the BIS values in the R0.5 and R0.6 groups were closely similar at all time points. Notably, one case in the R0.2 group had a BIS60 of 38 (duration <30 seconds), while all other cases had BISmin above 40; even at the highest dose (0.6 mg/kg), nearly twice the recommended induction dose,22 no burst suppression was observed.22,27–30 These results suggest that when remimazolam doses exceed 0.4 mg/kg, the sedative effect reaches a plateau, and further dose increases may not provide additional BIS benefit. Furthermore, no significant differences in BIS were observed between T30 and T60 across groups, suggesting that the BIS peak time for remimazolam may be around 60 seconds or later,27,31 highlighting the importance of monitoring timing in clinical practice. Tachycardia occurred immediately after remimazolam injection in 2 cases each in the R0.2, R0.4, and R0.5 groups, with a maximum rate of 107 bpm. Bradycardia was only occasionally observed across groups, with a minimum heart rate of 48 bpm; changes did not exceed 20% of baseline and were transient. Although three cases of systolic blood pressure below 90 mmHg occurred in the high-dose groups, they did not meet the hypotension criterion15,16 and improved after single-dose norepinephrine 4 μg intravenous administration. Apnea occurred in 2, 5, 5, 4, and 5 cases from the low-dose to high-dose groups, respectively. SpO2 decreases were mainly observed within 2 minutes after injection, with a minimum of 94%. The isolated decrease in SpO2 in the 0.4 mg/kg group at T300 was at the boundary of statistical significance (interaction P = 0.0485), appeared at only a single time point in multiple comparisons, and lacked a dose-dependent trend—the 0.5 mg/kg and 0.6 mg/kg groups did not show similar decreases. Even the lowest values remained above the clinical threshold, indicating that remimazolam’s effects on the cardiovascular and respiratory systems within this dose range are mild and manageable.32–34 Remimazolam-induced injection pain was not accompanied by limb withdrawal; body movements were minimal single movements of fingers or toes. Diaphragmatic spasm or cough occurred in isolated cases, possibly related to remimazolam’s relatively low selectivity for GABA neurotransmitters,35–37 or to higher doses,37 rapid administration,38 or inadequate sedation depth.39 This study had several limitations. First, BIS was recorded at discrete time points rather than continuously, and the observation period was limited to 300 seconds; further BIS decreases after 300 seconds cannot be excluded. Second, the ED90 estimated using the BIS ≤60 endpoint had an extremely wide confidence interval. Although sensitivity analysis confirmed the robustness of the results, this wide confidence interval itself suggests that BIS ≤60 may not be suitable for pharmacodynamic evaluation of remimazolam, or that a larger sample size and wider dose range are needed for stable estimation. The BIS ≤65 exploratory threshold, while supported by literature, requires further studies to confirm its correlation with postoperative outcomes. Third, this study did not include clinical sedation scales such as MOAA/S, and therefore cannot determine whether BIS ≤60 or BIS ≤65 is the more appropriate surgical sedation threshold—determining the optimal BIS threshold for remimazolam requires a dedicated prospective study incorporating clinical sedation reference indicators (eg, MOAA/S). Fourth, this study observed remimazolam as a single agent, whereas clinical anesthesia induction often involves multiple drugs with different mechanisms of action on BIS, particularly the strong synergistic effects of opioids;40 thus, extrapolation to polypharmacy scenarios should be cautious. Finally, this was a single-center study with a relatively small sample size, limited to Chinese adult patients with ASA I–II, and results may not be generalizable to elderly, obese, or high-comorbidity populations, requiring dedicated studies for validation. Conclusion A clear dose-dependent relationship exists between single-dose remimazolam and BIS, with good respiratory and circulatory safety in the 0.2–0.6 mg/kg range and a plateau effect above 0.4 mg/kg. The extremely wide confidence interval for the ED90 estimated using the BIS ≤60 criterion suggests that this endpoint may not be suitable for reliable pharmacodynamic evaluation of single-dose remimazolam. The ED estimates obtained with the BIS ≤65 threshold are post hoc exploratory findings and should serve only as a reference for future research; they require prospective validation in dedicated studies incorporating clinical sedation reference indicators (eg, MOAA/S) and should not be used as clinical dosing recommendations.